| | | |

Access to Multi-Modality Mesothelioma Treatment Limited for Uninsured & Rural Residents

access to multi-modality mesothelioma treatmentA new study shows a person’s insurance status and where they live often impact their access to multi-modality mesothelioma treatment. This can have an impact on their survival. 

Researchers at the University of Miami Sylvester Comprehensive Cancer Center conducted the new study. They shared their findings at the recent virtual world conference of the International Association for the Study of Lung Cancer. 

The study found that access to multi-modality mesothelioma treatment was more common in patients with private insurance or Medicare. It was also more common among those who lived closer to larger medical centers. 

People who lived further out or who did not have insurance often did not receive the treatments that offer the best odds of mesothelioma survival.

Disparities in Access to Multi-modality Mesothelioma Treatment

Malignant pleural mesothelioma is a lung-related cancer caused by exposure to asbestos. When people inhale asbestos dust, the fibers stay in the tissue indefinitely. Decades later, these people can develop tumors on the pleural membrane around the lungs. 

There is no single effective treatment for pleural mesothelioma. Patients who tend to have the best outcomes are those with access to multi-modality mesothelioma treatment. This usually means some combination of surgery, chemotherapy, immunotherapy, and/or radiation. 

Multiple studies show that surgery nearly always improves the odds of surviving mesothelioma. This is true regardless of what other mesothelioma therapies a person has. 

But mesothelioma is rare and mesothelioma surgery is complex. Many small-town hospitals never see a single case, let alone offer mesothelioma surgery. The Miami research shows this is causing a disparity in access to multi-modality mesothelioma treatment between rural residents and city-dwellers. 

Mesothelioma Options Greater in Cities

Previous studies show that up to 40 percent of pleural mesothelioma patients do not receive standard-of-care treatment. This is especially true for elderly patients. 

Oncologist Estelmari Rodriguez and her University of Miami colleagues wanted to know why. Is it a function of socioeconomic status, education, location, or something else?

They used the National Cancer Database to identify 2,804 patients with pleural mesothelioma. Patients received treatment between 2004 and 2017. 

Half of the patients had access to multi-modality mesothelioma treatment including surgery. More than half (57.3%) of these procedures took place at academic centers. These centers were mostly in urban areas where they have a higher volume of mesothelioma patients. 

“The majority of patients who had surgery were white, with private/Medicare insurance, and had access to multidisciplinary care in high-volume, academic facilities,” Dr. Rodriguez reported. “Very few patients who had surgery were uninsured or came from rural areas.”

Location and insurance status had a greater influence on access than income, race, other health problems, or education. But survival had more to do with the type of care they received. Patients who had access to multi-modality mesothelioma treatment with surgery had “significantly improved survival” over those who only had chemotherapy

“The findings of this study suggest that patients without access to expert multidisciplinary care at high-volume, academic facilities are being inappropriately undertreated for their disease due to lack of access,” Dr. Rodriguez concluded.

Source:

Rodriguez E. “Socioeconomic disparities in access to treatment and survival in operable malignant pleural mesothelioma in the United States”. Presented at: IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer; September 8-14, 2021. Abstract OA13.02. https://library.iaslc.org/conference-program?product_id=24&author=&category=&date=&session_type=&session=&presentation=&keyword=Socioeconomic%20Disparities%20in%20Access%20to%20Treatment%20&cme=undefined&

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…